SELLAS Life Sciences Group, Inc. (SLS) Form 8-K — Jun 25, 2026

$SLSForm 8-KItems 5.02, 9.01Filed Jun 25, 2026, 8:30 AM ET0001104659-26-077556Original filing

On June 24, 2026, SELLAS Life Sciences Group amended employment and severance agreements for CEO Dr. Angelos Stergiou, CFO John Burns, and CDO Dr. Dragan Cicic following a review of market practices. The amendment for Dr.

Key figures

Stergiou cic bonus multiplier: 1.5x
Stergiou cic severance months: 24
Burns cicic cic severance months: 15
Burns cicic non cic severance months: 9

Price after filing

1 day: 0.0%7 days: +26.0%30 days: +17.2%

Close on the filing date to close N calendar days later (from $10.53). Historical, not a forecast.

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.